| Original language | English (US) |
|---|---|
| Pages (from-to) | 990-991 |
| Number of pages | 2 |
| Journal | Alimentary Pharmacology and Therapeutics |
| Volume | 51 |
| Issue number | 10 |
| DOIs | |
| State | Published - May 1 2020 |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
- Pharmacology (medical)
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Alimentary Pharmacology and Therapeutics, Vol. 51, No. 10, 01.05.2020, p. 990-991.
Research output: Contribution to journal › Editorial › peer-review
TY - JOUR
T1 - Editorial
T2 - fluticasone propionate orally disintegrating tablets—interesting concept but is it going anywhere? Authors’ reply
AU - Hirano, Ikuo
AU - Safroneeva, Ekaterina
AU - Roumet, Marie C.
AU - Comer, Gail M.
AU - Eagle, Gina
AU - Schoepfer, Alain
AU - Falk, Gary W.
N1 - Funding Information: : IH has served as a consultant for Adare, Allakos, Arena, AstraZeneca, EsoCap, Gossamer, Receptos, Regeneron, and Shire/Takeda Pharmaceuticals. He has received research funding from Adare, Allakos, Receptos, Regeneron, and Shire. GMC is a consultant for Adare. ES has served as a consultant for Adare, Aptalis, Novartis, Receptos, and Regeneron. MCR has no conflicts of interest to report. AS has served as consultant for AbbVie, Adare, Falk Pharma GmbH, MSD, Receptos, Regeneron, Novartis, Pfizer, Takeda, Vifor. He received research funding from Adare, Falk Pharma GmbH, Receptos, Regeneron. GWF has received research support from Allakos, Receptos/Celgene, and Regeneron. He has received research support and has served as a consultant for Adare and Shire/Takeda. GE has served as a consultant for and is currently employed by Adare. Declaration of personal interests Funding Information: The author's declarations of personal and financial interests are unchanged from those in the original article.1 Declaration of personal interests: IH has served as a consultant for Adare, Allakos, Arena, AstraZeneca, EsoCap, Gossamer, Receptos, Regeneron, and Shire/Takeda Pharmaceuticals. He has received research funding from Adare, Allakos, Receptos, Regeneron, and Shire. GMC is a consultant for Adare. ES has served as a consultant for Adare, Aptalis, Novartis, Receptos, and Regeneron. MCR has no conflicts of interest to report. AS has served as consultant for AbbVie, Adare, Falk Pharma GmbH, MSD, Receptos, Regeneron, Novartis, Pfizer, Takeda, Vifor. He received research funding from Adare, Falk Pharma GmbH, Receptos, Regeneron. GWF has received research support from Allakos, Receptos/Celgene, and Regeneron. He has received research support and has served as a consultant for Adare and Shire/Takeda. GE has served as a consultant for and is currently employed by Adare.
PY - 2020/5/1
Y1 - 2020/5/1
UR - http://www.scopus.com/inward/record.url?scp=85083957613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083957613&partnerID=8YFLogxK
U2 - 10.1111/apt.15713
DO - 10.1111/apt.15713
M3 - Editorial
C2 - 32338781
AN - SCOPUS:85083957613
SN - 0269-2813
VL - 51
SP - 990
EP - 991
JO - Alimentary Pharmacology and Therapeutics
JF - Alimentary Pharmacology and Therapeutics
IS - 10
ER -